-
1.发明申请公开(公告)号：US20110207670A1
公开(公告)日：2011-08-25
申请号：US13126474
申请日：2009-10-21
IPC分类号： A61K38/17 , C07K14/435 , A61P13/12
CPC分类号： A61K38/366 , C07K14/7455
摘要： The present invention provides a method for preventing and/or treating a patient with acute kidney injury caused by a variety of conditions. The method comprises administering to the patient soluble thrombomodulin variants that do not bind thrombin. In conjunction with standard of care, soluble thrombomodulin variants that do not bind thrombin will prevent or reduce acute kidney injury and subsequent morbidity and mortality.
摘要翻译： 本发明提供一种预防和/或治疗由各种病症引起的急性肾损伤患者的方法。 该方法包括向患者施用不结合凝血酶的可溶性血栓调节蛋白变体。 结合护理标准，不结合凝血酶的可溶性血栓调节蛋白变体将预防或减少急性肾损伤及随后的发病率和死亡率。
-
公开(公告)号：US5948795A
公开(公告)日：1999-09-07
申请号：US882711
申请日：1997-06-25
IPC分类号： C07D333/52 , A61K31/38 , A61K31/381 , A61K31/445 , A61P5/00 , A61P9/00 , A61P17/00 , A61P29/00 , A61P35/00 , C07D333/56 , C07D333/66 , A61K31/40 , C07D409/12
CPC分类号： C07D333/66 , C07D333/56
摘要： Novel benzothiophenes, ##STR1## wherein R.sub.1, R.sub.2, and R.sub.3 are independently --OH, --OCO(C.sub.1 -C.sub.6 alkyl), --O(CO)O(C.sub.1 -C.sub.6 alkyl), --OCO--Ar, where Ar is phenyl or substituted phenyl, or --O(CO)O--phenyl; and R.sub.4 is N-pyrrolidinyl, N-piperidinyl, or N-hexamethyleneimino, and intermediates thereof, and the uses and formulations thereof, are provided by the present invention.
摘要翻译： 新的苯并噻吩其中R1，R2和R3分别是-OH，-OCO（C1-C6烷基），-O（CO）O（C1-C6烷基），-OCO-Ar，其中Ar是苯基或取代的苯基， 或-O（CO）O-苯基; R4为N-吡咯烷基，N-哌啶基或N-六亚甲基亚氨基及其中间体，其用途和配方由本发明提供。
-
公开(公告)号：US5792798A
公开(公告)日：1998-08-11
申请号：US892798
申请日：1997-07-15
IPC分类号： A61K31/138 , A61K31/135
CPC分类号： A61K31/138
摘要： Methods of inhibiting plasminogen activator inhibitor 1 comprising administering to a human in need thereof an effective amount of a compound having the formula I: ##STR1## wherein R.sup.1 and R.sup.2 are, independently, --H, --C.sub.1 -C.sub.4 alkyl, or taken together with the nitrogen to which they are attached form a pyrrolidine, piperidine, or hexamethyleneimino ring; or a pharmaceutically acceptable salt or solvate thereof.
摘要翻译： 抑制纤溶酶原激活物抑制剂1的方法包括向有需要的人施用有效量的具有式I的化合物：其中R 1和R 2独立地是-H，-C 1 -C 4烷基或一起 与它们相连的氮形成吡咯烷，哌啶或六亚甲基亚氨基环; 或其药学上可接受的盐或溶剂合物。
-
公开(公告)号：US5962698A
公开(公告)日：1999-10-05
申请号：US89521
申请日：1998-06-03
IPC分类号： C07D333/52 , A61K31/38 , A61K31/381 , A61K31/445 , A61P5/00 , A61P9/00 , A61P17/00 , A61P29/00 , A61P35/00 , C07D333/56 , C07D333/66 , C07D333/64
CPC分类号： C07D333/66 , C07D333/56
摘要： Novel benzothiophenes, and intermediates thereof, and the uses and formulations thereof, are provided by the present invention.
摘要翻译： 新的苯并噻吩及其中间体及其用途和配方由本发明提供。
-
公开(公告)号：US5780648A
公开(公告)日：1998-07-14
申请号：US882674
申请日：1997-06-25
IPC分类号： C07D333/52 , A61K31/38 , A61K31/381 , A61P5/00 , A61P9/00 , A61P17/00 , A61P29/00 , A61P35/00 , C07D333/56 , C07D333/64
CPC分类号： A61K31/381 , C07D333/56
摘要： Benzothiophenes, and uses and formulations thereof, are provided by the present invention.
摘要翻译： 苯并噻吩及其用途和制剂由本发明提供。
-
6.发明授权Effect of compounds that suppress induction of plasminogen activator inhibitor 1 (PAI-1) 失效抑制纤溶酶原激活物抑制剂1（PAI-1）诱导的化合物的作用
公开(公告)号：US5980938A
公开(公告)日：1999-11-09
申请号：US882673
申请日：1997-06-25
IPC分类号： A61K9/00 , A61K9/20 , A61K9/48 , A61K31/4025 , A61K31/453 , A61K47/36
CPC分类号： A61K9/0095 , A61K31/4025 , A61K31/453 , A61K9/2059 , A61K9/4866 , A61K47/36 , Y10S514/882
摘要： The present invention provides methods of inhibiting PAI-1 using benzopyrans.
摘要翻译： 本发明提供使用苯并吡喃抑制PAI-1的方法。
-
公开(公告)号：US5731328A
公开(公告)日：1998-03-24
申请号：US708868
申请日：1996-09-04
IPC分类号： A61K31/38 , A61K31/00 , A61K31/381 , A61K31/40 , A61K31/4025 , A61K31/445 , A61K31/4465 , A61K31/4523 , A61K31/4535 , A61K31/55 , A61P5/36 , A61P7/00 , A61P7/02 , A61P9/10 , A61P31/00 , A61P43/00
CPC分类号： A61K31/55 , A61K31/381 , A61K31/4025 , A61K31/4535
摘要： A method of inhibiting plasminogen activator inhibitor 1 comprising administering to a human in need thereof an effective amount of a compound having the formula ##STR1## wherein R.sup.1 and R.sup.3 are independently hydrogen, --CH.sub.3, ##STR2## wherein Ar is optionally substituted phenyl; R.sup.2 is selected from the group consisting of pyrrolidine, hexamethyleneimino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof.
摘要翻译： 抑制纤溶酶原激活物抑制剂1的方法包括向有需要的人施用有效量的具有式（I）的化合物，其中R 1和R 3独立地是氢，-CH 3， 苯基; R2选自吡咯烷，六亚甲基亚氨基和哌啶子基; 或其药学上可接受的盐的溶剂合物。
-
公开(公告)号：US07638123B2
公开(公告)日：2009-12-29
申请号：US11678684
申请日：2007-02-26
申请人： Angelina Vucic Ciaccia , Lawrence Mark Gelbert , Brian William Grinnell , Bryan Edward Jones , David Eugene Joyce
发明人： Angelina Vucic Ciaccia , Lawrence Mark Gelbert , Brian William Grinnell , Bryan Edward Jones , David Eugene Joyce
CPC分类号： A61K38/4866 , C12Q1/56 , G01N33/86 , G01N2333/96461 , G01N2500/00 , Y10S530/868
摘要： Method of treating a disease or pathological condition with activated protein C or a compound having activated protein C activity by direct regulation of the expression of specific genes associated with the disease or pathological condition.
摘要翻译： 通过直接调节与疾病或病理状况相关的特定基因的表达，用活化蛋白C或具有活化的蛋白C活性的化合物治疗疾病或病理状况的方法。
-
公开(公告)号：US07204981B2
公开(公告)日：2007-04-17
申请号：US10221538
申请日：2001-03-21
申请人： Angelina Vucic Ciaccia , Lawrence Mark Gelbert , Brian William Grinnell , Bryan Edward Jones , David Eugene Joyce
发明人： Angelina Vucic Ciaccia , Lawrence Mark Gelbert , Brian William Grinnell , Bryan Edward Jones , David Eugene Joyce
IPC分类号： A61K38/48 , A61K38/00 , C07K14/435
CPC分类号： A61K38/4866 , C12Q1/56 , G01N33/86 , G01N2333/96461 , G01N2500/00 , Y10S530/868
摘要： Method of treating a disease or pathological condition with activated protein C or a compound having activated protein C activity by direct regulation of the expression of specific genes associated with the disease or pathological condition.
摘要翻译： 通过直接调节与疾病或病理状况相关的特定基因的表达，用活化蛋白C或具有活化的蛋白C活性的化合物治疗疾病或病理状况的方法。
-
公开(公告)号：US6008199A
公开(公告)日：1999-12-28
申请号：US174507
申请日：1998-10-16
IPC分类号： C12N15/09 , A61K20060101 , A61K38/00 , A61K38/02 , A61K38/12 , A61K38/36 , A61K38/48 , A61P7/00 , A61P7/02 , A61P11/00 , A61P15/00 , A61P17/02 , A61P31/00 , A61P31/04 , A61P41/00 , A61P43/00 , C12N20060101 , C12N9/64 , C12N15/00 , C12P21/00 , A61K38/01 , A61K37/547
CPC分类号： A61K38/4866 , C12N9/6464 , C12Y304/21069 , Y10S514/802
摘要： A method of treatment for human patients with an acquired hypercoagulable state or acquired protein C deficiency associated with sepsis, purpura fulminans, meningococcal sepsis, bone marrow and other transplantations, severe burns, pregnancy, major surgery, severe trauma, or ARDS, which comprises administering activated protein C providing a highly selective therapeutic agent with a low potential for causing bleeding complications.
-
-
-
-
-
-
-
-
-
搜索结果
18 条记录 (耗时 0.03 秒)
